Cascadian Therapeutics

The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Type
Public
HQ
Seattle, US
Size (employees)
53 (est)
Cascadian Therapeutics is headquartered in Seattle, US

Cascadian Therapeutics Office Locations

Cascadian Therapeutics has office in Seattle
Seattle, US

Cascadian Therapeutics Metrics

Cascadian Therapeutics Summary

Market capitalization

$97.7 M

Closing share price

$4.3
Cascadian Therapeutics's current market capitalization is $97.7 M.

Cascadian Therapeutics Market Value History

Cascadian Therapeutics Company Life

You may also be interested in